This work aimed first to prepare deproteinized natural rubber latex (DNRL) and investigate the properties of films after it was blended with various adhesive polymers: hydroxypropylmethyl cellulose (HPMC), methyl cellulose (MC), sodium carboxymethyl cellulose (SCMC), poly(vinyl alcohol) (PVA), poloxamer 407, and sodium alginate. The second aim was to identify the films that would be the best for medical and pharmaceutical applications. Dibutyl phthalate (DBP), diethyl phthalate, dibutyl sebacate, triethyl citrate, and glycerin (GLY) were used as plasticizers to improve the elasticity and adhesiveness of the novel materials. DNRL was prepared by proteolytic alcalase enzyme treatment, followed by centrifugation. The DNRL was virtually free of protein, produced no significant reaction in the rabbit skin irritation test, and formed a good elastic film, but it had low skin adhesive properties. Blending DNRL with several polymers produced better films with different elastic and adhesive properties. Moisture uptake and swelling tests indicated that its films provided increasing hydrophilicity when blended with several polymers. SEM showed homogeneous films, and water hydraulic permeability tests indicated some porosity in matrix films. Blending DNRL with HPMC or PVA and DBP or GLY produced films with the best potential for novel materials. FT-IR, DSC, and XRD studies indicated the compatibility of the blended ingredients. In conclusion, DNRL blends could be used suitably for medical and pharmaceutical applications.
Nicotine matrix films were prepared using DNRL/HPMC blends
for
transdermal delivery. Several plasticizers were also mixed. The mechanical
and physicochemical properties, moisture uptake, and swelling ratio
of films depended on HPMC and plasticizers. The compatibility of each
ingredient in the blended films was confirmed by FT-IR, XRD, and DSC.
The in vitro release of nicotine showed a monophasic
slow release pattern. The polymer and plasticizer blends produced
a faster release rate. The kinetics of nicotine release from the films
fitted the diffusion type. Surprisingly, the permeation of the nicotine
into the skin occurred by zero-order kinetics. It was concluded that
nicotine matrix films could be produced that could provide a controlled
release of the drug and suitable permeation patterns. Moreover, they
were safe to apply to the skin as they did not cause irritation.
Film forming polymeric solutions were prepared from DNRL blended with MC, PVA, or SAG, together with dibutylphthalate or glycerine used as plasticizers. These formulations were easily prepared by simple mixing. In a preliminary step, in situ films were prepared by solvent evaporation in a Petri-dish. Their mechanical and physicochemical properties were determined. The in vitro release and skin permeation of nicotine dissolved in these blended polymers were investigated by a modified Franz diffusion cell. The formulations had a white milky appearance, and were homogeneous and smooth in texture. Their pH was suitable for usage in skin contact. The mechanical property of in situ films depended on the ingredients but all compatible films were in an amorphous phase. The DNRL/PVA was shown to be the most suitable mixture to form completed films. The in vitro release and skin permeation studies demonstrated a biphasic release that provided an initial rapid release followed by a constant release rate that fitted the Higuchi's model. Nicotine loaded DNRL/PVA series were selected for the stability test for 3 months. These formulations needed to be kept at 4°C in tight fitting containers. In conclusion, film forming polymeric solutions could be developed for transdermal nicotine delivery systems.
The crystallization of mefenamic acid in transdermal patch is a major problem that makes the patch unstable and decreases the drug release. The additive was used to inhibit crystallization of a mefenamic acid. Among the different types of additives, polyvinylpyrrolidone (PVP) K30 and PVP K90 were studied and found to be highly effective in inhibiting the crystallization of the drug. The PVP presented as a solubilizer agent for mefenamic acid in matrix patches at the different ratio between drug : PVP, 1 : 2 and 1 : 2.5 for using PVP K30 and 1 : 1.5 and 1 : 2 for using PVP K90. The characterizations showed the homogeneous patches without the crystal form of the mefenamic acid in matrix patches. The release profiles of the mefenamic acid from the patches were investigated by Franz diffusion cells. Over the first 1 h, the release behavior of mefenamic acid from the patches obviously increased when PVP was used as a crystallization inhibitor. However, the ratio between drug : PVP K90 at 1 : 2 was found to be the most effective in increasing the drug release from patch. Thus, the PVP could be used as a crystallization inhibitor for mefenamic acid in matrix patches which will increase the drug release.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.